KR20220100992A - 브루톤 티로신 키나제 억제제의 투여 - Google Patents

브루톤 티로신 키나제 억제제의 투여 Download PDF

Info

Publication number
KR20220100992A
KR20220100992A KR1020227022407A KR20227022407A KR20220100992A KR 20220100992 A KR20220100992 A KR 20220100992A KR 1020227022407 A KR1020227022407 A KR 1020227022407A KR 20227022407 A KR20227022407 A KR 20227022407A KR 20220100992 A KR20220100992 A KR 20220100992A
Authority
KR
South Korea
Prior art keywords
day
cycle
days
administered
btk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227022407A
Other languages
English (en)
Korean (ko)
Inventor
바바라 진 브랜드후버
노라 치엔 이 쿠
니샤 난다
스티븐 어거스트 스미스
도널드 차이
Original Assignee
록쏘 온콜로지, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 록쏘 온콜로지, 인코포레이티드 filed Critical 록쏘 온콜로지, 인코포레이티드
Priority to KR1020237028538A priority Critical patent/KR20230127372A/ko
Publication of KR20220100992A publication Critical patent/KR20220100992A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227022407A 2019-12-06 2020-12-03 브루톤 티로신 키나제 억제제의 투여 Ceased KR20220100992A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237028538A KR20230127372A (ko) 2019-12-06 2020-12-03 브루톤 티로신 키나제 억제제의 투여

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962944674P 2019-12-06 2019-12-06
US62/944,674 2019-12-06
US202063077996P 2020-09-14 2020-09-14
US63/077,996 2020-09-14
US202063109698P 2020-11-04 2020-11-04
US63/109,698 2020-11-04
PCT/US2020/063089 WO2021113497A1 (en) 2019-12-06 2020-12-03 Dosing of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237028538A Division KR20230127372A (ko) 2019-12-06 2020-12-03 브루톤 티로신 키나제 억제제의 투여

Publications (1)

Publication Number Publication Date
KR20220100992A true KR20220100992A (ko) 2022-07-18

Family

ID=73854977

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227022407A Ceased KR20220100992A (ko) 2019-12-06 2020-12-03 브루톤 티로신 키나제 억제제의 투여
KR1020237028538A Pending KR20230127372A (ko) 2019-12-06 2020-12-03 브루톤 티로신 키나제 억제제의 투여

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237028538A Pending KR20230127372A (ko) 2019-12-06 2020-12-03 브루톤 티로신 키나제 억제제의 투여

Country Status (10)

Country Link
US (1) US12551463B2 (cg-RX-API-DMAC7.html)
EP (1) EP4069219A1 (cg-RX-API-DMAC7.html)
JP (3) JP7142173B2 (cg-RX-API-DMAC7.html)
KR (2) KR20220100992A (cg-RX-API-DMAC7.html)
CN (1) CN115175677A (cg-RX-API-DMAC7.html)
AU (2) AU2020397034B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009716A2 (cg-RX-API-DMAC7.html)
IL (1) IL292882B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022006631A (cg-RX-API-DMAC7.html)
WO (1) WO2021113497A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US20150291554A1 (en) 2012-11-02 2015-10-15 Pfizer Inc. Bruton's Tyrosine Kinase Inhibitors
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
CN114605327B (zh) * 2015-12-16 2025-03-11 洛克索肿瘤学股份有限公司 可用作激酶抑制剂的化合物
WO2017132474A1 (en) 2016-01-30 2017-08-03 Newave Pharmaceutical Inc. Bcl-2 inhibitors
KR102376764B1 (ko) 2016-08-05 2022-03-18 더 리젠츠 오브 더 유니버시티 오브 미시건 Bcl-2 억제제로서의 n-(페닐설포닐)벤즈아미드 및 관련 화합물
CN110177788B (zh) 2017-01-07 2023-03-24 重庆复创医药研究有限公司 作为bcl-2选择性凋亡诱导剂的化合物
SI3612531T1 (sl) 2017-04-18 2022-11-30 Shanghai Fochon Pharmaceutical Co., Ltd. Sredstva, ki sprožajo apoptozo
JP2020528061A (ja) 2017-07-26 2020-09-17 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト BET阻害剤、Bcl−2阻害剤及び抗CD20抗体を用いた併用療法
IL316472A (en) 2018-01-10 2024-12-01 Recurium Ip Holdings Llc Benzamide compounds
CN112437772B (zh) 2018-04-29 2023-11-21 百济神州有限公司 Bcl-2抑制剂
CA3108065C (en) 2018-07-31 2025-10-07 Loxo Oncology, Inc. SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE
KR20220100992A (ko) * 2019-12-06 2022-07-18 록쏘 온콜로지, 인코포레이티드 브루톤 티로신 키나제 억제제의 투여

Also Published As

Publication number Publication date
EP4069219A1 (en) 2022-10-12
KR20230127372A (ko) 2023-08-31
CN115175677A (zh) 2022-10-11
AU2024201263B2 (en) 2025-05-01
JP2022177119A (ja) 2022-11-30
IL292882B1 (en) 2026-05-01
US12551463B2 (en) 2026-02-17
AU2020397034A1 (en) 2022-07-21
AU2024201263A1 (en) 2024-03-14
BR112022009716A2 (pt) 2022-08-09
IL292882A (en) 2022-07-01
JP2025098099A (ja) 2025-07-01
NZ788615A (en) 2024-10-25
CA3160417A1 (en) 2021-06-10
US20230041515A1 (en) 2023-02-09
MX2022006631A (es) 2022-09-07
AU2020397034B2 (en) 2023-12-07
JP7142173B2 (ja) 2022-09-26
JP7654604B2 (ja) 2025-04-01
WO2021113497A1 (en) 2021-06-10
JP2022518974A (ja) 2022-03-17

Similar Documents

Publication Publication Date Title
EP3458091B1 (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
US20230107195A1 (en) Treatment of cancer with smg1-inhibitors
US20170306050A1 (en) Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases
CN110325191A (zh) 以较少的副作用治疗egfr-驱动的癌症
UA125216C2 (uk) Комбінована терапія
US20160287588A1 (en) Methods of treating a bruton's tyrosine kinase disease or disorder
AU2024201263B2 (en) Dosing of a Bruton's Tyrosine Kinase inhibitor
CA3107023A1 (en) Ep4 inhibitors and synthesis thereof
JP2016522247A (ja) 組合せ医薬
KR20210106483A (ko) Mdm2 억제제를 위한 확장된 저용량 요법
WO2021207598A1 (en) Combination treatment with an agonist of p53 and a second therapeutic agent
JP5393691B2 (ja) 急性ヒト骨髄性白血病細胞を死滅させるトロンボポエチン受容体作用薬(TpoRA)
CN101969947B (zh) 使用诸如呋咯地辛的pnp抑制剂与烷化剂或抗cd20剂的组合治疗血液学癌症的方法
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
CA3160417C (en) Dosing of a bruton's tyrosine kinase inhibitor
EA051944B1 (ru) Введение доз ингибитора тирозинкиназы брутона
EA046722B1 (ru) Введение доз ингибитора тирозинкиназы брутона
NZ788615A9 (en) Dosing of a bruton's tyrosine kinase inhibitor
AU2012321091B2 (en) Methods of treating a Bruton's Tyrosine Kinase disease or disorder
HK40004756A (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors
HK40004756B (en) Combination therapy with notch and pd-1 or pd-l1 inhibitors

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
PA0105 International application

Patent event date: 20220630

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220630

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20220630

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230119

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230527

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230119

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230822